Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

08.06.2021 | case report

Breast implant-associated anaplastic large-cell lymphoma: a European case report and literature review

verfasst von: Federico Ghidinelli, M.D., Luigi Filippini, M.D., Paola Porsio, M.D., Federico Canzi, M.D., Rino Balzano, M.D., Elisa Flocchini, M.D., Anna Bianchi, M.D.

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Summary

Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCLC) is an infrequent T‑cell neoplasm that accounts for approximately 3% of non-Hodgkin lymphomas. After the first case of BIA-ALCL, an increasing number of scientific works concerning BIA-ALCL have been published. We report and discuss the case of BIA-ALCL in a 66-year-old Caucasian woman presented with swelling, pain, redness and a seroma that had developed around the breast implant. After establishing the diagnosis of BIA-ALCL (stage IC, T3N0M0 according to the BIA-ALCL staging system), she underwent several breast implant procedures and capsulectomies. We also provide the results of a literature review on the incidence, clinical management, diagnosis and therapy of this disease.
“Level of evidence: level IV case report with literature review”
Vorheriger Artikel Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer
Nächster Artikel Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities
Literatur
1.
2.
Berry MG, Davies DM. Breast augmentation: part i—a review of the silicone prosthesis. J Plast Reconstr Aesthet Surg. 2010;63:1761–8.PubMed
3.
Spear SL, Parikh PM, Goldstein JA. History of breast implants and the food and drug administration. Clin Plast Surg. 2009;36:15–21.PubMed
4.
Berry MG, Cucchiara V, Davies DM. Breast augmentation: part III-preoperative considerations and planning. J Plast Reconstr Aesthet Surg. 2011;64:1401–9.PubMed
5.
Xu J, Wei S. Breast implant-associated anaplastic large cell lymphoma: review of a distinct clinicopathologic entity. Arch Pathol Lab Med. 2014;138:842–6.PubMed
6.
Bizjak M, Selmi C, Praprotnik S, et al. Silicone implants and lymphoma: the role of inflammation. J Autoimmun. 2015;65:64–73.PubMed
7.
Thompson PA, Lade S, Webster H, Ryan G, Prince HM. Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity. Haematologica. 2010;95:1977–9.PubMedPubMedCentral
8.
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.PubMedPubMedCentral
9.
McCarthy CM, Loyo-Berríos N, Qureshi AA, et al. Patient registry and outcomes for breast implants and anaplastic large cell Lymphoma etiology and epidemiology (PROFILE): initial report of findings, 2012–2018. Plast Reconstr Surg. 2019;143:65S–73S.PubMedPubMedCentral
10.
Groth K, Graf R. Breast implant-associated anaplastic large cell Lymphoma (BIA-ALCL) and the textured breast implant crisis. Aesthetic Plast Surg. 2020;44:1–12.
11.
di Pompeo FS, Sorotos M, Clemens MW, Firmani G, European Association of Plastic Surgeons (EURAPS) Committee on device safety and development. Breast Implant–Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Review of epidemiology and prevalence assessment in Europe. Aesthet Surg J. 2020. https://​doi.​org/​10.​1093/​asj/​sjaa285.CrossRef
12.
Quesada AE, Medeiros LJ, Clemens MW, Ferru MC, Miranda RN, Miranda RN. Breast implant-associated anaplastic large cell lymphoma: a review disorder. Modern Pathol. 2019;32:166–188.
13.
Case Report guidelines C. CARE Checklist of information to include when writing a case report. 2016; : 13.
14.
Grant Stevens W, Bradley Calobrace M, Alizadeh K, Zeidler KR, Harrington JL, d’Incelli RC. Ten-year core study data for sientra’s food and drug administration—approved round and shaped breast implants with cohesive silicone gel. Plast Reconstr Surg. 2018;141:7S–19S.PubMed
15.
Kendall B, Sawyer RJ, Chang H, et al. No 主観的健康感を中心とした在宅高齢者における 健康関連指標に関する共分散構造分析 Title. Foresight. 2019;23:1–9.
16.
Gunawardana RT, Dessauvagie BF, Taylor DB. Breast implant-associated anaplastic large cell lymphoma, an under-recognised entity. J Med Imaging Radiat Oncol. 2019;63:630–8.PubMed
17.
Gidengil CA, Predmore Z, Mattke S, Van Busum K, Kim B. Breast implant-associated anaplastic large cell lymphoma: a systematic review. Plast Reconstr Surg. 2015;135:713–20.PubMed
18.
Yoshida SH, Swan S, Teuber SS, Gershwin ME. Silicone breast implants: immunotoxic and epidemiologic issues. Life Sci. 1995;56:1299–310.PubMed
19.
Kricheldorff J, Fallenberg EM, Solbach C, Gerber-Schäfer C, Rancsó C, Von Fritschen U. Brustimplantat-assoziiertes Lymphom. Dtsch Arztebl Int. 2018;115:625–35. übersichtsarbeit.
20.
Lazzeri D, Agostini T, Bocci G, et al. ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. Clin Breast Cancer. 2011;11:283–96.PubMed
21.
Zucca E, Bertoni F, Vannata B, Cavalli F. Emerging role of infectious etiologies in the pathogenesis of marginal zone B‑cell lymphomas. Clin Cancer Res. 2014;20:5207–16.PubMed
22.
Hu H, Jacombs A, Vickery K, Merten SL, Pennington DG, Deva AK. Chronic biofilm infection in breast implants is associated with an increased t‑cell lymphocytic infiltrate: Implications for breast implant-associated lymphoma. Plast Reconstr Surg. 2015;135:319–29.PubMed
23.
Hu H, Johani K, Almatroudi A, et al. Bacterial biofilm infection detected in breast implant-associated anaplastic large-cell lymphoma. Plast Reconstr Surg. 2016;137:1659–69.PubMed
24.
Laurent C, Nicolae A, Laurent C, et al. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL. Blood. 2020;135:360–70.PubMedPubMedCentral
25.
Technologies A, Diego S. Targeted next generation sequencing of breast implant—associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A. Br J Haematol. 2018;180:735–760.
26.
27.
Tabanelli V, Corsini C, Fiori S, et al. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant–associated anaplastic large cell lymphomas. Hum Pathol. 2019;90:60–9.PubMed
28.
29.
Chacko A, Lloyd T. Breast implant-associated anaplastic large cell lymphoma: a pictorial review. Insights Imaging. 2018;9:683–6.PubMedPubMedCentral
30.
Marra A, Viale G, Pileri SA, et al. Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. Cancer Treat Rev. 2020;84:101963.PubMed
31.
Freeman. 乳鼠心肌提取 HHS public access. Physiol Behav. 2018;176:139–48.
32.
Leberfinger AN, Behar BJ, Williams NC, et al. Breast implant-associated anaplastic large cell lymphoma: a systematic review. JAMA Surg. 2017;152:1161–8.PubMed
33.
Brody GS, Deapen D, Taylor CR, et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 casesa. Plast Reconstr Surg. 2015;135:695–705.PubMed
34.
Doren EL, Miranda RN, Selber JC, et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017;139:1042–50.PubMed
35.
Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J . 2019;39:S3–S13.PubMed
36.
Mehta-Shah N, Clemens MW, Horwitz SM. How I treat breast implant–associated anaplastic large cell lymphoma. Blood. 2018;132:1889–98.PubMedPubMedCentral
37.
Chott A, Vonderheid EC, Olbricht S, Miao NN, Balk SP, Kadin ME. The same dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol. 1996;106:696–700.PubMed
38.
Laurent C, Delas A, Gaulard P, et al. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol. 2016;27:306–14.PubMed
39.
Ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma layouts systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 2000;53:445–50.PubMed
40.
Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913–21.PubMed
41.
Munakata W, Terauchi T, Maruyama D, Nagai H. Revised staging system for malignant lymphoma based on the Lugano classification. Jpn J Clin Oncol. 2019;49:895–900.PubMed
42.
Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34:160–8.PubMed
43.
Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21.PubMed
44.
Prince HM, Kim YH, Horwitz S, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T‑cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390:555–66.PubMed
45.
Johnson L, O’Donoghue JM, McLean N, et al. Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent. Eur J Surg Oncol. 2017;43:1393–401.PubMed
46.
Zimmerman A, Locke FL, Emole J, et al. Recurrent systemic anaplastic lymphoma kinase–negative anaplastic large cell lymphoma presenting as a breast implant–associated lesion. Cancer Control. 2015;22:369–72.PubMed
47.
Hwang MJ, Brown H, Murrin R, Momtahan N, Sterne GD. Breast implant-associated anaplastic large cell Lymphoma: a case report and literature review. Aesthetic Plast Surg. 2015;39:391–5.PubMed
48.
Tardío JC, Granados R. Axillary lymphadenopathy: an outstanding presentation for breast implant-associated ALK-negative anaplastic large cell lymphoma. Int J Surg Pathol. 2015;23:424–8.PubMed
49.
50.
Clemens MW, Miranda RN, Butler CE. Breast implant informed consent should include the risk of anaplastic large cell lymphoma. Plast Reconstr Surg. 2016;137:1117–22.PubMed
51.
Platt J, Baxter N, Zhong T. Breast reconstruction after mastectomy for breast cancer. CMAJ. 2011;183:2109–16.PubMedPubMedCentral
52.
Somogyi RB, Ziolkowski N, Osman F, Ginty A, Brown M. Breast reconstruction: updated overview for primary care physicians. Can Fam Physician. 2018;64:424–32.PubMedPubMedCentral
Metadaten
Titel
Breast implant-associated anaplastic large-cell lymphoma: a European case report and literature review
verfasst von
Federico Ghidinelli, M.D.
Luigi Filippini, M.D.
Paola Porsio, M.D.
Federico Canzi, M.D.
Rino Balzano, M.D.
Elisa Flocchini, M.D.
Anna Bianchi, M.D.
Publikationsdatum
08.06.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00714-4

Weitere Artikel der Ausgabe 3/2022

Multiple myeloma with central nervous system relapse: a case report

  • case report

Publisher Correction: Brain metastases: new systemic treatment approaches

  • Open Access
  • Publisher Correction

Neoadjuvant treatment for solid tumors—the earlier, the better

  • editorial

Neoadjuvant treatment in gastric cancer

  • short review

CAR T cells in multiple myeloma: Where we stand and where we might be going

  • short review

Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities

  • comment